Say goodbye to layover woes and hello to unforgettable adventures with Turkish Airlines' Stopover Istanbul and Touristanbul programmes
Treating severe Covid-19 patients with an anti-cancer drug may reduce mortality and speed up recovery, a new study suggests.
According to a small clinical study, published in the journal Nature Communications, the drug called bevacizumab may be beneficial for Covid-19 patients.
"Our findings suggest that bevacizumab plus standard care is highly beneficial for patients with severe Covid-19 and should be considered as a potential first-line therapeutic regimen for this group," said researcher Yihai Cao from the Karolinska Institutet in Sweden.
Bevacizumab is a medication that has been used to treat various types of cancer since 2004. It works by slowing the formation of new blood vessels by inhibiting a growth factor known as VEGF. Many patients with severe Covid-19 have elevated levels of VEGF as well as symptoms associated with this marker, including excess fluid and disorganized blood vessels in the lungs. Against this background, the researchers designed a clinical trial to investigate the effect of combining bevacizumab with standard care for treating patients with severe Covid-19.
For the study, the team recruited 26 confirmed Covid-19 patients with symptoms such as difficulty in breathing, low blood oxygen levels and pneumonia. They were retrospectively matched with 26 patients of similar characteristics who received standard care at the same hospitals in roughly the same time period and thus served as the control group.
The recruits received standard care plus a single low dose of about 7.5 mg/kg bevacizumab, which markedly improved blood oxygen levels within 24 hours compared to the control group.
By the end of the 28-day follow-up period, 92 per cent of the bevacizumab-treated patients no longer needed the same level of oxygen support as before the trial began, compared with an improvement rate of 62 per cent for the controls.
None of the bevacizumab-treated patients died and 17 (65 per cent) improved so much that they were able to leave the hospital within the follow-up period. In the control group, three died and only 46 per cent were discharged within 28 days. The drug also shortened the duration of oxygen-support to a median of nine days compared with 20 for the standard care group.
Say goodbye to layover woes and hello to unforgettable adventures with Turkish Airlines' Stopover Istanbul and Touristanbul programmes
It will be important to watch if the central bank nudges the South Asian currency higher as a slight downward bias is likely to persist in the market, says expert
K. Padmarajan, a 65-year-old tyre repair shop owner, began fighting elections in 1988 from Tamil Nadu state
Certificate need to be presented at check-in for inspection prior to flying from Abu Dhabi, says airline
'I do not remember the last time I broke my fast with my family,' says the officer manning Al Mizher intersection
The emerging technology stands poised to transform logistics — providing swifter, more efficient, and eco-conscious delivery options in the years to come
Among other variants of yellow metal, 22K opened at Dh246.25, 21K at Dh238.25 and 18K at Dh204.25 per gram
The incident happened before the boarding started; all affected passengers had to be rebooked on another flight